Julia Katharina Schwarze (Recipient)

A phase I clinical trial on intratumoral administration of autologous CD1c(BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma
Awarded date7 Feb 2020
Degree of recognitionNational
Awarded at eventBACR Annual Meeting 2020

ID: 52711772